RxDoctor Payments Data

Christian Hyde, MD

Radiation Oncology · Flint, MINPI 1316972086

Payments from drug & device makers

$985in general payments, 2019–2025

Across 14 payments — averaging $70.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • IBA Proton Therapy, Inc.$361
  • Siemens Medical Solutions USA, Inc.$194
  • Novocure Inc.$182
  • Merck$47
  • Progenics Pharmaceuticals, Inc.$44
  • Boston Scientific$43
  • plus $114 from 5 others

What the payments were for

  • Food & beverage$985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
IBA Proton Therapy, Inc.1$361
Siemens Medical Solutions USA, Inc.1$194
Novocure Inc.1$182
Merck3$47
Progenics Pharmaceuticals, Inc.1$44
Boston Scientific1$43
Myovant Sciences Inc.2$37
Icotec Medical Inc.1$34
Novartis1$16
Ion Beam Applications S.A.1$15
Pharmaand GmbH1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 65th percentile of 198 radiation oncology providers in Michigan.

See all radiation oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$180,745
Medicare patients
234
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix48$153,873
Tamsulosin Hcl70$2,023
Bicalutamide19$765
Dexamethasone14$296
Levetiracetam18$278

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →